Wednesday, September 30, 2020
Jellagen® Limited, a marine biotechnology company producing high-value collagen derived from jellyfish, has entered into a licensing agreement to grant exclusive patent rights for the development to the Mayo Clinic treatment of vocal cord paralysis.
Vocal cord paralysis (VCP) is an injury to one or both of the recurrent laryngeal nerves (RLN) that control most of the muscles in the larynx, resulting in paralysis of the vocal cord muscles, which in turn can result in l airway obstruction, dyspnoea, vocal changes, etc. Vocal cord paralysis is caused by the side effects of surgery, trauma, cancer, and more.
The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.
Contacts
Adam Watts, Digital Marketing Manager at Jellagen
Tel .: +44 (0) 3333 583 299
www.jellagen.co.uk
